MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

KU-57788

CAS No. : 503468-95-9

MCE 站：KU-57788

产品活性：KU-57788 (NU7441) 是一种高效的选择性 DNA-PK 抑制剂，IC₅₀ 为 14 nM。 KU-57788 是 NHEJ 通路抑制剂。KU-57788 还抑制 PI3K 和 mTOR，IC₅₀ 分别为 5.0 和 1.7 μM。

研究领域：Cell Cycle/DNA Damage  |  PI3K/Akt/mTOR

作用靶点：DNA-PK  |  CRISPR/Cas9

In Vitro: NU7441 (0.5 to 10 ?M) inhibits the growth of liver cancer HepG2 cells dose- and time-dependently. NU7441 reduces pDNA-PKcs (S2056) protein expression in liver cancer cells. Furthermore, double treatment of NU7441 and 60Coγ IR affects DNA damage repair. NU7441 is solvent-exposed in BRD4, this inhibitor can be classified as a Type I BRD inhibitor. NU7441 reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

In Vivo: KU-57788 (0.5 to 10 ?M) inhibits the growth of liver cancer HepG2 cells dose- and time-dependently. KU-57788 reduces pDNA-PKcs (S2056) protein expression in liver cancer cells. Furthermore, double treatment of KU-57788 and 60Coγ IR affects DNA damage repair. KU-57788 weakly inhibits BRD4 and BRDT with IC₅₀s of 1 μM and 3.5 μM, respectively. KU-57788 is solvent-exposed in BRD4, this inhibitor can be classified as a Type I BRD inhibitor. KU-57788 reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

相关产品：Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  LY294002  |  Brefeldin A  |  Nocodazole  |  PI-103  |  Zidovudine  |  RS-1  |  SCR7 pyrazine  |  LTURM34  |  L755507  |  YU238259  |  Compound 401  |  AMA-37

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。